We have located links that may give you full text access.
ENGLISH ABSTRACT
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
[Clinical outcome of FLT3-ITD (+) acute myeloid leukemia patients treated with allogeneic hematopoietic stem cell transplantation].
OBJECTIVE: To study the clinical outcome of patients with fms-like tyrosine kinase-3 internal tandem duplication (FLT3-ITD) positive acute myeloid leukemia (AML) treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT) and to explore the potential prognostic factors to patients' survival including transplant types or disease status.
METHODS: A total of 314 AML patients in our center from October 2006 to October 2012 were retrospectively analyzed, among whom, 54 patients were defined with FLT3-ITD positive. Survival rates and treatment-related mortality were further analyzed.
RESULTS: For all 54 FLT3-ITD positive patients, the 3-year overall survival (3-OS) rate was 56% and 3-year leukemia-free survival (3-LFS) rate was 47%. The outcome of haplo-identical HSCT was similar as that of sibling donors (3-OS rate: 60% vs 54%; 3-LFS rate: 54% vs 45%, respectively) . There were 47 patients who received transplantation in first complete remission (CR1) . The other 7 patients were of disease relapse or in CR2 before transplantation. Not surprisingly, patients in CR1 had better prognosis than those in non-CR1.
CONCLUSIONS: Allo-HSCT is an effective treatment for AML patients with FLT3-ITD positive mutation. The survival outcome of haplo-identical HSCT was comparable with that of sibling donors. Relapse of AML was the dominant factor related to the mortality of FLT3-ITD positive AML patients after allo-HSCT.
METHODS: A total of 314 AML patients in our center from October 2006 to October 2012 were retrospectively analyzed, among whom, 54 patients were defined with FLT3-ITD positive. Survival rates and treatment-related mortality were further analyzed.
RESULTS: For all 54 FLT3-ITD positive patients, the 3-year overall survival (3-OS) rate was 56% and 3-year leukemia-free survival (3-LFS) rate was 47%. The outcome of haplo-identical HSCT was similar as that of sibling donors (3-OS rate: 60% vs 54%; 3-LFS rate: 54% vs 45%, respectively) . There were 47 patients who received transplantation in first complete remission (CR1) . The other 7 patients were of disease relapse or in CR2 before transplantation. Not surprisingly, patients in CR1 had better prognosis than those in non-CR1.
CONCLUSIONS: Allo-HSCT is an effective treatment for AML patients with FLT3-ITD positive mutation. The survival outcome of haplo-identical HSCT was comparable with that of sibling donors. Relapse of AML was the dominant factor related to the mortality of FLT3-ITD positive AML patients after allo-HSCT.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app